Dr. David S. Smith to Head Regulatory and Quality Affairs
DUBLIN, Calif., Aug. 17 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that Audrey F. Jakubowski, Ph.D., Chief Regulatory and Quality Officer will retire effective today. Dr. Jakubowski's primary responsibilities have been transitioned to David S. Smith, Ph.D., who earlier this year joined SuperGen as Vice President, Regulatory and Quality Affairs.
"Dr. Jakubowski has been extremely instrumental in guiding and growing SuperGen's regulatory and quality efforts over the years," said Dr. James Manuso, President and CEO. "A valued colleague, Audrey created and nurtured a highly effective organization and approach to regulatory affairs and quality management that the Company will continue under Dr. David Smith's leadership."
Dr. Smith, 52, joined SuperGen in March 2007. Prior to joining
SuperGen, Dr. Smith was Senior Director, Regulatory Strategy at Wyeth
Consumer Healthcare. His responsibilities included obtaining new product
registrations on a global level, US marketed product support, and providing
scientific and regulatory guidance to business development initiatives.
From 1996 to 2000, Dr. Smith served as Regulatory Affairs Program Director
at Roche Pharma. Dr. Smith began his regulatory career in 1987 at
Schering-Plough, where he focused on the development and registration of
oncology and biotechnology products. During his tenure at Schering-Plough,
he concentrated on European Union activities and major markets outside of
the U.S. Dr. Smith's training includes
|SOURCE SuperGen Inc.|
Copyright©2007 PR Newswire.